Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer

NCT03370367 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

189

Enrollment

NETWORK

Sponsor class

Conditions

Stage I-II Head and Neck Cancer

Interventions

DRUG: 13-cis retinoic acid
OTHER: Placebo

Sponsor

Eastern Cooperative Oncology Group